Association of Visceral Obesity Indices With Survival Among Cancer Survivors: Evidence From Two Nationally Population‐Based Cohort Study Authors: Qiang Li, Yao Wang, Qingchun Liu, Wei Zhang Published: 2026 ABSTRACT ABSTRACTBackgroundObesity is critical for cancer prognosis, but the impact of visceral obesity indices on survival in cancer survivors remains unclear. This study explored associations between six visceral obesity indices, BMI, and overall survival using two large population‐based cohorts of cancer survivors.MethodsA retrospective cohort study was conducted using data from the 2001 to 2018 National Health and Nutrition Examination Survey (NHANES) and China Health and Retirement Longitudinal Study (CHARLS). Visceral obesity was assessed by a body shape index (ABSI), conicity index (ConI), visceral adiposity index (VAI), Chinese visceral adiposity index (CVAI), metabolic score for visceral fat (METS‐VF), and lipid accumulation product (LAP). Kaplan–Meier curves, multivariable Cox regression, restricted cubic splines (RCS), mediation analysis, subgroup, and sensitivity analyses were employed.ResultsThe study included 1783 NHANES survivors (weighted population: 8,556,033; weighted median follow‐up 85 months) and 162 CHARLS patients (weighted population: 5,631,233; weighted median follow‐up 37 months). Only ABSI was significantly associated with increased all‐cause mortality risk in both cohorts (p < 0.05). In NHANES, individuals in the highest ABSI level had 80% increased mortality risk compared to the lowest level (adjusted HR 1.80; p for trend = 0.004), consistent with CHARLS. RCS showed a linear ABSI‐mortality relationship. Mediation analyses indicated that neutrophil mediated 16.77% proportion of the ABSI‐mortality association in NHANES. Subgroup analyses and sensitivity analyses further confirmed these findings.ConclusionCompared to other indices, ABSI may be a valuable, potentially independent predictor of survival in cancer survivors, highlighting its value for clinical assessment to identify high‐risk individuals and guide targeted interventions. Abbreviations a body shape index aggregate index of systemic inflammation analysis of variance complete blood count China Health and Retirement Longitudinal Study confidence intervals conicity index Chinese visceral adiposity index fasting blood glucose high‐density lipoprotein cholesterol hazard ratios interquartile ranges lipid accumulation product metabolic score for visceral fat monocyte‐to‐lymphocyte ratio National Health and Nutrition Examination Survey neutrophil‐to‐lymphocyte ratio overall survival platelet‐to‐lymphocyte ratio restricted cubic splines standard deviation systemic inflammation index systemic inflammation response index triglycerides visceral adiposity index variance inflation factor waist circumference Background Cancer survivors represent a growing population due to advances in early detection and treatment, but they remain at elevated risk for morbidity and mortality from cancer recurrence, cardiovascular disease, and other causes [1, 2]. Additionally, the quality of life of cancer survivors is compromised, resulting in a significant burden on public health [3]. Hence, identifying robust markers that predict survival outcomes in this population is critical for tailoring follow‐up care and interventions. Obesity has emerged as a major modifiable factor influencing cancer incidence, progression, and prognosis worldwide, with accumulating evidence highlighting its critical role in shaping patient outcomes [4, 5, 6]. Traditionally, body mass index (BMI) has been the most widely used anthropometric measure to define and classify obesity due to its simplicity and accessibility. However, BMI has inherent limitations, most notably its inability to distinguish between different types of fat deposits, such as visceral and subcutaneous adiposity [7]. This limitation is particularly important because visceral fat—fat stored within the abdominal cavity around internal organs has been shown to confer greater metabolic and inflammatory risks compared to subcutaneous fat [8]. Thus, reliance on BMI alone may inadequately capture the specific risks associated with central or visceral obesity. Visceral adiposity has garnered increasing attention because of its strong links to metabolic dysfunction, systemic inflammation, and a range of adverse health outcomes, including cardiovascular disease and cancer‐related morbidity [9, 10]. Characterizing visceral fat accurately is therefore critical to understanding its contribution to disease processes. While imaging modalities such as dual‐energy X‐ray absorptiometry, computed tomography, magnetic resonance imaging, and dual bioelectrical impedance analysis are considered gold standards for measuring abdominal adiposity, their use in routine clinical practice and large‐scale population studies is limited [11]. These methods are often costly, time‐consuming, and in some cases involve radiation exposure, which restricts their applicability for widespread screening or longitudinal monitoring. Advanced optical and molecular imaging approaches also show potential for tumor prognostic evaluation, yet they remain largely confined to experimental and specialized clinical settings [12, 13]. To overcome these practical challenges, researchers have developed several surrogate indices that estimate visceral fat accumulation using easily obtainable anthropometric and biochemical parameters. These indices include the a body shape index (ABSI) [14], conicity index (ConI) [15], visceral adiposity index (VAI) [16], Chinese visceral adiposity index (CVAI) [17], metabolic score for visceral fat (METS‐VF) [18], and lipid accumulation product (LAP) [19]. In general populations, these visceral obesity indices have demonstrated superior predictive value for cardiometabolic risks compared to BMI, suggesting that they may better capture the harmful physiological effects of central fat accumulation [18, 20]. A critical research gap persists, however: data on how these various visceral obesity indices are associated with survival among cancer survivors remain limited and fragmented. Cancer survivors represent a unique population with distinct metabolic and immunological profiles shaped by their underlying disease and treatments (including chemotherapy, radiation, and surgery) that often induce profound alterations in body composition, inflammation, and metabolic homeostasis [21]. While the prognostic utility of visceral obesity indices has been well established in general populations and patients with cardiovascular or metabolic diseases, their ability to predict survival outcomes specifically in cancer survivors has not been systematically evaluated. Existing studies in this cohort are sparse, often focusing on a single index rather than comparing multiple indices, and fail to clarify which of these surrogate measures best captures visceral adiposity‐related survival risk in this distinct population [21]. Furthermore, the biological mechanisms linking visceral adiposity to adverse outcomes in cancer survivors remain incompletely understood. Systemic inflammation and immune dysregulation have been proposed as key mediators [22], yet their specific roles and interactions have not been fully elucidated. Addressing this gap is essential: a clear understanding of which visceral obesity indices hold prognostic value for cancer survivors would enable more precise risk stratification, while illuminating the underlying mechanisms could inform targeted interventions aimed at reducing mortality and improving quality of life in cancer survivorship. In this context, we conducted a multi‐center, retrospective cohort study to investigate the relationships between six visceral obesity indices and BMI with all‐cause mortality among cancer survivors utilizing comprehensive datasets from two large‐scale population‐based studies: the National Health and Nutrition Examination Survey (NHANES) and the China Health and Retirement Longitudinal Study (CHARLS). We further explored dose–response associations using restricted cubic splines and conducted mediation analysis to uncover potential underlying pathways. Our study aims to provide novel insights into the prognostic significance of visceral adiposity assessment in cancer survivorship care. This cohort study has been reported in line with the STROBE guideline. Methods Study Design and Patients The National Health and Nutrition Examination Survey (NHANES) is a nationally representative program that systematically collects health‐related data on the noninstitutionalized civilian population of the United States. Utilizing a stratified, multistage probability sampling design, NHANES has been conducted in continuous 2‐year cycles since 1999 to assess the health and nutritional status of the US population. All NHANES protocols were approved by the National Center for Health Statistics (NCHS) Research Ethics Review Board, and written informed consent was obtained from all participants. The China Health and Retirement Longitudinal Study (CHARLS) is a prospective cohort study of adults aged 45 years and older, conducted across 28 provinces in China, and adopts a multi‐stage probability sampling method. Notably, some individuals aged 40–44 years were also enrolled at baseline [23]. CHARLS is an ongoing survey with follow‐up examinations conducted every 2–3 years. Ethical approval for the CHARLS study was granted by the Peking University Institutional Review Board. As a secondary analysis of anonymized data, the study did not involve direct contact with participants; therefore, additional informed consent and institutional review board approval were not required. For our analysis, we included cancer survivors identified in the NHANES database spanning nine survey cycles from 2001 through 2018. From the CHARLS database, participants with cancer who attended the 2011 and 2015 surveys, years when blood samples were collected, were included. Body measurements and blood biomarker assessments for the NHANES and CHARLS cohorts are described in the Appendix S1. Initially, 4780 participants with cancer were identified in NHANES and 301 in CHARLS. We applied the following exclusion criteria to ensure data completeness and relevance: For NHANES participants: (1) age < 20 years (n = 0); (2) pregnant participants (n = 22); (3) survival time < 6 months or missing (n = 66); (4) missing information on seven body measurements (BMI, ABSI, ConI, VAI, CVAI, METS‐VF, LAP; n = 2902); and (5) missing inflammation indicators (neutrophils, monocyte, platelet, lymphocyte; n = 7). For CHARLS participants: (1) missing information on age (n = 3); (2) pregnant participants (n = 0); (3) survival time < 6 months or missing (n = 31); and (4) missing information on seven body measurements (BMI, ABSI, ConI, VAI, CVAI, METS‐VF, LAP; n = 105). After applying these criteria, the final analytic sample comprised 1783 participants from the NHANES cohort and 162 participants from the CHARLS cohort (Figure 1). Flow chart of participant selection. CHARLS, China Health and Retirement Longitudinal Study; NHANES, National Health and Nutrition Examination Survey. Assessment of Cancer Information on participants' cancer history was extracted from specific sections within each database. In the NHANES database, cancer history was obtained from the “Medical Conditions” section. Participants were classified as cancer survivors if they answered “yes” to the question: “Have you ever been told by a doctor or other health professional that you had cancer or malignancy of any kind?” Similarly, in the CHARLS database, cancer history was derived from the section titled “Doctor Diagnosed Health Problems: Ever Had Condition”. Participants who responded “yes” to the question “ever had cancer?” were identified as cancer survivors. Assessment of Six Visceral Obesity Indices and BMI In this study, we evaluated six visceral obesity indices: ABSI, ConI, VAI, CVAI, METS‐VF, and LAP. These indices were selected intentionally to cover the full spectrum of currently validated visceral adiposity surrogates, ensuring a comprehensive comparison of their prognostic utility in cancer survivors [18, 24, 25]. These indices were calculated using a combination of anthropometric measurements and peripheral blood test results. Specifically, body measurements included height, weight, and waist circumference (WC), while blood biomarkers comprised triglycerides (TG), fasting blood glucose (FBG), and high‐density lipoprotein cholesterol (HDL). Based on these variables, the following formulas were used to compute ABSI, CI, VAI, CVAI, METS‐VF, LAP, and BMI (Table 1). Their definitions were summarized in Table 1. TABLE 1The descriptions of six visceral obesity indices and BMI.IndicesDefinitionsFormulasRequired variablesA Body Shape Index (ABSI) [14]A metric integrating waist circumference, height, and BMI to reflect body shape and visceral fat distribution. ABSI=WC/100Height/1001/2×BMI2/3 WC (cm) BMI (kg/m2) Height (cm) Conicity Index (ConI)An index estimating abdominal fat distribution relative to body size [15]. CI=WC/1000.109×WeightHeight/100 WC (cm) Weight (kg) Height (cm) Visceral Adiposity Index (VAI)A sex‐specific index combining anthropometric and metabolic parameters to estimate visceral adiposity [16]. VAIMales=WC39.68+1.88×BMI×TG/88.61.03×1.31HDL/38.66 VAIFemales=WC36.58+1.89×BMI×TG/88.60.81×1.52HDL/38.66 WC (cm) BMI (kg/m2) TG (mg/dL) HDL (mg/dL) Sex Chinese Visceral Adiposity Index (CVAI)A modified index for Chinese populations, incorporating age and metabolic markers [17]. CVAIMales=−267.93+0.68×Age+0.03×BMI+4×WC+22×log10TG/88.6−16.32×HDL/38.66 CVAIFemales=−187.32+1.71×Age+4.23×BMI+1.12×WC+39.76×log10TG/88.6−11.66×HDL/38.66 Age (years) BMI (kg/m2) WC (cm) TG (mg/dL) HDL (mg/dL) Sex Metabolic Score for Visceral Fat (METS‐VF)A composite score estimating visceral fat using metabolic and anthropometric data [18]. METS−VF=4.466+0.011×lnMETS−IR3+3.239×lnWCHeight3+0.319×SexMale=1Female=0+0.594×lnAge METS−IR=ln2×FBG+TG×BMIlnHDL FBG (mg/dL) TG (mg/dL) BMI (kg/m2) HDL (mg/dL) WC (cm) Height (cm) Sex Age (years) Lipid Accumulation Product (LAP)An index combining waist circumference and triglycerides to assess lipid‐related fat accumulation [19]. LAPMales=WC−65×TG/88.6 LAPFemales=WC−58×TG/88.6 WC (cm) TG (mg/dL) Sex Body Mass Index (BMI)A standard measure of overall adiposity [7]. BMI=WeightHeight/1002 Weight (kg) Height (cm) The descriptions of six visceral obesity indices and BMI. WC (cm) BMI (kg/m2) Height (cm) WC (cm) Weight (kg) Height (cm) VAIMales=WC39.68+1.88×BMI×TG/88.61.03×1.31HDL/38.66 VAIFemales=WC36.58+1.89×BMI×TG/88.60.81×1.52HDL/38.66 WC (cm) BMI (kg/m2) TG (mg/dL) HDL (mg/dL) Sex CVAIMales=−267.93+0.68×Age+0.03×BMI+4×WC+22×log10TG/88.6−16.32×HDL/38.66 CVAIFemales=−187.32+1.71×Age+4.23×BMI+1.12×WC+39.76×log10TG/88.6−11.66×HDL/38.66 Age (years) BMI (kg/m2) WC (cm) TG (mg/dL) HDL (mg/dL) Sex METS−VF=4.466+0.011×lnMETS−IR3+3.239×lnWCHeight3+0.319×SexMale=1Female=0+0.594×lnAge METS−IR=ln2×FBG+TG×BMIlnHDL FBG (mg/dL) TG (mg/dL) BMI (kg/m2) HDL (mg/dL) WC (cm) Height (cm) Sex Age (years) LAPMales=WC−65×TG/88.6 LAPFemales=WC−58×TG/88.6 WC (cm) TG (mg/dL) Sex Weight (kg) Height (cm) Mortality Ascertainment The primary outcome of this study was all‐cause mortality. Mortality status for the NHANES cohort was ascertained using the publicly available linked mortality file, which connects NHANES participants to the National Death Index through a probabilistic matching method. For the CHARLS cohort, all‐cause mortality data were obtained from the Harmonized CHARLS dataset (Version D, June 2021). In cases where the exact date of death was missing in CHARLS, the date of death was assigned based on the survey wave in which the participant was reported deceased: if death occurred during the current wave, the date of that wave was used; if death was reported in a previous wave, the date of that earlier wave was assigned. The follow‐up period was calculated as the number of months from the date of the participant's interview to either the date of death or, for those who remained alive, the date of the last available survey. Assessment of Covariates Covariates extracted from both databases included age (continuous variable), sex (male/female), education level, smoking status, and history of chronic diseases. Education level was categorized as low (middle school and below) or high (high school and above). Smoking status was classified as smokers (including current and former smokers) or never smokers/unknown. History of chronic diseases—specifically hypertension, hypercholesterolemia, and diabetes—was based on self‐reported physician diagnoses. Sex was self‐reported by participants in both NHANES and CHARLS datasets, with no additional information collected regarding gender identity. All covariates were obtained through standardized household interview questionnaires. The variable of cancer type was extracted exclusively from the NHANES database, as the CHARLS database does not contain this variable. Specifically, cancer type was classified into skin, breast, prostate, cervix, melanoma, and other categories, with this ordering based on the top five tumors by quantity in the NHANES database. Additionally, baseline measurements of height, weight, WC, FBG, TG, HDL, LDL, and TC were collected and treated as continuous variables in both datasets. Inflammation biomarkers were only derived from complete blood count (CBC) test results available in the NHANES dataset, as the CHARLS dataset does not contain such data. The laboratory methods for CBC measurements are detailed on the NHANES website. The selected biomarkers included neutrophils, lymphocytes, platelets, monocytes, as well as calculated ratios and indices: neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), monocyte‐to‐lymphocyte ratio (MLR), systemic inflammation response index (SIRI = neutrophils × monocytes/lymphocytes), systemic inflammation index (SII = neutrophils × platelets/lymphocytes), and aggregate index of systemic inflammation (AISI = neutrophils × monocytes × platelets/lymphocytes). Statistical Analysis Participants were classified into three groups based on the optimal cut‐off values of visceral obesity indices and BMI determined by the X‐tile software (Version 3.6.1, Yale University School of Medicine). For both the NHANES and CHARLS databases, continuous variables are presented as medians with interquartile ranges (IQR), while categorical variables are expressed as counts and percentages. All analyses employed weighted methods to account for the complex sampling design, ensuring national representativeness (Appendix S1). Continuous variables were presented as weighted means with standard errors and compared using one‐way analysis of variance (ANOVA). Categorical variables were reported as unweighted frequencies with weighted proportions and compared using chi‐square tests. To examine the associations between six visceral obesity indices, BMI, and all‐cause mortality, weighted Kaplan–Meier curves were generated to estimate survival over time in the NHANES dataset and CHARLS dataset, with log‐rank tests used to compare survival distributions across groups. Multivariate Cox regression models were also applied to the two databases. Results are presented as hazard ratios (HRs) with 95% confidence intervals (CIs). Five models were constructed: Model 1 was unadjusted; Model 2 adjusted for age and sex; Model 3 further adjusted for education level, smoking status, and history of hypertension, hypercholesterolemia, diabetes, and cancer type (note: cancer type stratification was not applicable to the CHARLS cohort); Model 4 additionally adjusted for height, weight, WC, FBG, TC, HDL, LDL, and TG; and Model 5 adjusted the variables in Model 4 with a variance inflation factor (VIF) less than 10 because a VIF greater than 10 indicates a high degree of multicollinearity among variables. Model 3 was constructed to control for core clinical and lifestyle confounders without incorporating indicators that are biologically or mathematically coupled with visceral obesity indices. By contrast, Models 4 and 5 were established to further verify whether the prognostic performance of visceral obesity indices, especially ABSI, remained potential independent of its own constituent indicators and conventional metabolic biomarkers. To explore potential non‐linear relationships between visceral obesity indices, BMI, and all‐cause mortality, restricted cubic spline (RCS) analyses were performed. Mediation analyses were conducted using the “CMAverse” package in R to assess whether inflammatory biomarkers (neutrophils, lymphocytes, platelets, monocytes, NLR, PLR, MLR, SIRI, SII, and AISI) mediated the associations between visceral obesity indices and mortality. These analyses employed the bootstrap method with 1000 iterations and were adjusted according to Model 5 covariates. A mediating effect was considered present if the indirect effect, total effect were statistically significant and if the proportion mediated was positive. Mediation analysis was conducted only in the NHANES cohort, as the CHARLS cohort did not provide data on inflammatory markers. To further validate the robustness of the association between ABSI and all‐cause mortality in the NHANES and CHARLS cohorts, we conducted subgroup analyses adjusted for Model 5. These analyses were stratified by different cancer types, sex, educational levels, smoking status, and the presence of conditions including hypertension, hypercholesterolemia, and diabetes. In sensitivity analyses, we conducted four types of assessments to ensure the robustness of our findings. First, we employed multiple imputation to address missing data, thereby preventing potential biases arising from incomplete information from affecting the results (Appendix S1). Second, to examine the stability of ABSI across different populations, we applied the same cut‐off values used in the NHANES dataset to the CHARLS dataset, aiming to evaluate the relationship between ABSI and prognosis among cancer survivors. Meanwhile, we further re‐categorized ABSI using conventional quartile grouping, a standard approach widely used in epidemiological studies, to avoid potential optimistic bias introduced by the data‐driven X‐tile cutoff. Third, for survival data, we additionally included participants with a follow‐up time of 0 to 6 months on the basis of the primary analysis and performed both weighted and unweighted Kaplan–Meier analyses as well as Model 5‐based weighted COX regression analyses in both cohorts. Fourth, we used the E‐value to assess the potential impact of unmeasured confounding; specifically, a higher E‐value indicates that stronger unmeasured confounders would be required to explain the observed association. All weighted regression analyses and smooth curve fittings were performed using appropriate functions from the “survey” package in R. All statistical tests were two‐sided, with p < 0.05 considered statistically significant. All analyses and graphical representations were conducted using R software (version 4.3.0). Results Patient and Clinical Characteristics Of the 5081 cancer survivors in the NHANES and CHARLS cohorts, 1945 met the inclusion criteria and were included in the study (Figure 1). The optimal cut‐off values of six visceral obesity indices and BMI in both the NHANES and CHARLS cohorts, which were determined using X‐Tile Software based on overall survival (OS), are presented in Figures S1 and S2. Tables 2 and 3 showed the characteristics of the participants according to the different ABSI levels among HNANES cohort and CHARLS cohort. TABLE 2Characteristics of cancer survivors in the NHANES cohort according to different ABSI levels.Characteristics a TotalABSI_L (≤ 8.20 × 10−2)ABSI_M (8.20 × 10−2 < ABSI < 8.87 × 10−2)ABSI_H (≥ 8.87 × 10−2) p N 1783567923293Age, years, Median (IQR)64.00 (53.00, 74.00)54.00 (45.00, 66.00)66.00 (58.00, 75.00)75.00 (67.00, 80.00)< 0.001SexMale822 (42.22%)142 (24.09%)504 (51.77%)176 (55.68%)< 0.001Female961 (57.78%)425 (75.91%)419 (48.23%)117 (44.32%)Education levelLow‐educated381 (13.54%)97 (10.48%)198 (13.31%)86 (22.48%)< 0.001High‐educated1401 (86.46%)469 (89.52%)725 (86.69%)207 (77.52%)SmokingYes976 (53.27%)271 (44.85%)527 (57.69%)178 (59.60%)0.002No/Unknown807 (46.73%)296 (55.15%)396 (42.31%)115 (43.45%)HypertensionYes1001 (50.83%)263 (39.65%)554 (55.60%)184 (63.18%)< 0.001No/Unknown782 (49.17%)304 (60.35%)369 (44.40%)109 (36.82%)HypercholesterolemiaYes861 (48.35%)229 (41.22%)480 (51.23%)152 (56.82%)0.001No/Unknown922 (51.65%)338 (58.78%)443 (48.77%)141 (43.18%)DiabetesYes333 (14.31%)68 (8.23%)183 (14.79%)82 (28.69%)< 0.001No/Unknown1450 (85.69%)499 (91.77%)740 (85.21%)211 (71.31%)Cancer typeSkin431 (29.85%)121 (28.66%)240 (30.99%)70 (28.87%)< 0.001Breast268 (15.26%)118 (21.97%)110 (10.22%)40 (15.75%)Prostate257 (9.35%)36 (2.10%)164 (13.08%)57 (15.04%)Cervix268 (8.27%)118 (12.38%)110 (7.12%)40 (1.54%)Melanoma109 (7.30%)31 (6.47%)58 (7.71%)20 (8.00%)Other594 (29.97%)188 (28.41%)304 (30.87%)102 (30.81%)Height, cm167.11 (160.60, 175.20)164.60 (159.33, 172.01)168.60 (161.56, 176.62)168.03 (161.10, 175.40)< 0.001Weight, kg78.90 (66.50, 92.80)75.90 (64.10, 91.40)81.35 (69.10, 93.60)75.70 (66.28, 90.96)0.011WC, cm100.10 (89.44, 110.87)92.31 (82.90, 104.43)102.60 (93.49, 112.61)106.39 (99.00, 117.20)< 0.001FBG, mg/dL103.00 (94.00, 114.73)99.00 (92.00, 108.00)104.00 (96.00, 116.21)110.00 (100.00, 126.00)< 0.001TC, mg/dL194.00 (169.00, 223.00)196.00 (173.00, 223.00)194.00 (165.00, 223.00)187.00 (161.00, 219.73)0.016HDL, mg/dL53.00 (43.00, 66.00)57.00 (47.00, 70.15)51.00 (42.00, 63.00)51.00 (43.00, 60.00)< 0.001LDL, mg/dL113.00 (89.00, 138.00)113.00 (93.00, 139.00)114.00 (87.00, 138.00)107.00 (81.57, 134.00)0.005TG, mg/dL109.00 (78.00, 159.00)97.00 (70.00, 145.01)113.55 (80.00, 166.02)127.00 (92.30, 177.07)< 0.001BMI, kg/m2 27.56 (24.10, 32.36)27.40 (23.68, 33.20)27.90 (24.52, 32.50)27.20 (24.20, 30.87)0.180ABSI8.37 × 10−2 (8.04 × 10−2, 8.68 × 10−2)7.93 × 10−2 (7.72 × 10−2, 8.07 × 10−2)8.52 × 10−2 (8.36 × 10−2, 8.66 × 10−2)9.05 × 10−2 (8.95 × 10−2, 9.22 × 10−2)< 0.001ConI1.34 (1.27, 1.40)1.26 (1.21, 1.30)1.36 (1.32, 1.40)1.45 (1.41, 1.49)< 0.001VAI1.54 (0.94, 2.64)1.30 (0.79, 2.31)1.63 (0.99, 2.81)1.88 (1.24, 3.21)< 0.001CVAI150.26 (110.19, 193.81)117.29 (77.20, 166.55)160.30 (126.08, 201.60)182.38 (145.99, 224.70)< 0.001METS‐VF6.58 (6.22, 6.87)6.26 (5.75, 6.61)6.68 (6.40, 6.91)6.90 (6.68, 7.05)< 0.001LAP47.44 (27.28, 81.94)36.03 (19.99, 63.49)51.82 (30.88, 87.32)66.00 (43.70, 93.47)< 0.001Neutrophil, 109/L3.80 (2.96, 4.90)3.50 (2.80, 4.70)3.80 (3.00, 4.90)4.20 (3.32, 5.30)< 0.001Lymphocyte, 109/L1.70 (1.40, 2.20)1.80 (1.50, 2.20)1.70 (1.40, 2.10)1.70 (1.40, 2.10)0.586Monocyte, 109/L0.50 (0.40, 0.70)0.50 (0.40, 0.60)0.50 (0.40, 0.70)0.60 (0.50, 0.70)< 0.001Platelet, 109/L231.00 (192.00, 273.00)237.00 (198.00, 283.37)227.31 (190.00, 270.00)227.00 (185.60, 270.00)0.050NLR2.15 (1.63, 3.00)2.00 (1.55, 2.75)2.21 (1.67, 3.11)2.37 (1.76, 3.43)< 0.001PLR133.89 (106.05, 167.99)133.77 (107.89, 171.76)133.12 (105.52, 167.82)134.28 (103.76, 167.00)0.709MLR0.31 (0.23, 0.40)0.27 (0.21, 0.36)0.31 (0.24, 0.42)0.33 (0.25, 0.45)< 0.001SIRI1.12 (0.75, 1.69)0.97 (0.66, 1.44)1.20 (0.80, 1.71)1.37 (0.89, 2.15)< 0.001SII495.93 (357.00, 720.00)468.03 (331.73, 690.23)501.00 (370.53, 720.00)551.15 (386.64, 772.67)0.026AISI260.93 (169.17, 406.67)229.65 (148.71, 372.12)278.55 (180.72, 415.63)294.83 (194.13, 500.55)< 0.001All‐cause mortalityYes554 (23.21%)100 (11.92%)308 (26.56%)146 (41.03%)< 0.001No1229 (76.79%)467 (88.08%)615 (73.44%)147 (58.97%)Follow‐up time (months)85.00 (46.00, 135.00)104.00 (50.00, 151.00)80.00 (46.00, 132.00)67.96 (39.00, 108.00)< 0.001Abbreviations: ABSI, a body shape index; AISI, aggregate index of systemic inflammation; BMI, body mass index; ConI, conicity index; CVAI, Chinese visceral adiposity index; FBG, fasting blood glucose; HDL, high‐density lipoprotein cholesterol; IQR, the interquartile range; LAP, lipid accumulation product; LDL, low‐density lipoprotein cholesterol; METS‐VF, metabolic score for visceral fat; MLR, monocyte/lymphocyte ratio; NHANES, National Health and Nutrition Examination Survey; NLR, neutrophil/lymphocyte ratio; PLR, platelet/lymphocyte ratio; SII, systemic inflammation index; SIRI, systemic inflammation response index; TC, total cholesterol; TG, triglyceride; VAI, visceral adiposity index; WC, waist circumference. a Survey data were presented as weighted median (IQR) for continuous variables, and unweighted frequencies (weighted proportions) for categorical variables. Characteristics of cancer survivors in the NHANES cohort according to different ABSI levels. Abbreviations: ABSI, a body shape index; AISI, aggregate index of systemic inflammation; BMI, body mass index; ConI, conicity index; CVAI, Chinese visceral adiposity index; FBG, fasting blood glucose; HDL, high‐density lipoprotein cholesterol; IQR, the interquartile range; LAP, lipid accumulation product; LDL, low‐density lipoprotein cholesterol; METS‐VF, metabolic score for visceral fat; MLR, monocyte/lymphocyte ratio; NHANES, National Health and Nutrition Examination Survey; NLR, neutrophil/lymphocyte ratio; PLR, platelet/lymphocyte ratio; SII, systemic inflammation index; SIRI, systemic inflammation response index; TC, total cholesterol; TG, triglyceride; VAI, visceral adiposity index; WC, waist circumference. Survey data were presented as weighted median (IQR) for continuous variables, and unweighted frequencies (weighted proportions) for categorical variables. TABLE 3Characteristics of cancer survivors in the CHARLS cohort according to different ABSI levels.Characteristics a TotalABSI_L (≤ 8.50 × 10−2)ABSI_M (8.50 × 10−2 < ABSI < 8.89 × 10−2)ABSI_H (≥ 8.89 × 10−2) p N 1621162620Age, years, Median (IQR)57.02 (50.00, 65.00)56.00 (49.00, 64.00)55.19 (49.00, 63.00)67.37 (57.92, 72.10)< 0.001SexMale53 (30.81%)42 (34.54%)7 (23.31%)4 (16.42%)0.208Female109 (69.19%)74 (65.46%)19 (76.69%)16 (83.58%)Education levelLow‐educated146 (89.12%)103 (87.44%)24 (92.95%)19 (95.21%)0.478High‐educated16 (10.88%)13 (12.56%)2 (7.05%)1 (4.79%)SmokingYes43 (23.19%)32 (24.12%)7 (24.28%)4 (16.42%)0.725No/Unknown119 (76.81%)84 (75.88%)19 (75.72%)16 (83.58%)HypertensionYes52 (30.00%)33 (25.33%)12 (50.94%)7 (35.59%)0.075No/Unknown110 (70.00%)83 (74.67%)14 (49.06%)13 (64.41%)HypercholesterolemiaYes59 (33.43%)39 (31.71%)12 (39.17%)8 (37.59%)0.751No/Unknown103 (66.57%)77 (68.29%)14 (60.83%)12 (62.41%)DiabetesYes29 (16.00%)11 (9.65%)8 (30.54%)10 (38.74%)0.002No/Unknown133 (84.00%)105 (90.35%)18 (69.46%)10 (61.26%)Height, cm156.70 (152.16, 162.01)157.29 (153.10, 162.07)154.89 (151.53, 160.25)153.77 (150.74, 156.21)0.146Weight, kg59.44 (53.40, 66.26)59.59 (53.36, 66.61)62.02 (53.40, 64.61)53.95 (49.67, 63.78)0.426WC, cm86.50 (79.77, 93.91)84.55 (78.16, 92.00)90.48 (86.01, 97.04)92.64 (86.77, 103.36)0.001FBG, mg/dL100.90 (91.62, 110.65)99.10 (91.09, 108.00)105.84 (96.74, 123.92)104.81 (97.73, 174.40)0.046TC, mg/dL183.28 (165.08, 203.26)178.87 (157.79, 201.03)194.17 (171.15, 198.63)201.27 (166.62, 222.66)0.098HDL, mg/dL48.47 (42.19, 57.22)48.41 (42.42, 57.27)43.16 (37.59, 49.15)52.55 (45.31, 58.66)0.069LDL, mg/dL102.67 (83.82, 124.00)100.39 (83.42, 121.07)110.20 (92.66, 123.98)119.15 (80.39, 125.43)0.505TG, mg/dL113.13 (82.02, 169.92)109.73 (75.96, 160.29)161.52 (87.61, 179.82)134.67 (109.72, 179.51)0.021BMI, kg/m2 23.66 (21.55, 26.50)23.66 (21.57, 26.43)25.07 (20.93, 27.44)22.39 (20.93, 27.03)0.749ABSI8.24 × 10−2 (8.03 × 10−2, 8.51 × 10−2)8.03 × 10−2 (7.85 × 10−2, 8.11 × 10−2)8.44 × 10−2 (8.39 × 10−2, 8.62 × 10−2)9.13 × 10−2 (9.01 × 10−2, 9.23 × 10−2)< 0.001ConI1.29 (1.24, 1.34)1.27 (1.23, 1.31)1.35 (1.33, 1.38)1.42 (1.40, 1.46)< 0.001VAI2.07 (0.98, 3.07)1.68 (0.94, 2.80)3.21 (1.53, 4.46)2.35 (1.91, 3.40)0.012CVAI102.61 (78.80, 131.02)92.10 (63.62, 121.21)114.59 (86.97, 131.21)131.49 (111.34, 159.80)0.003METS‐VF6.28 (5.89, 6.54)6.14 (5.78, 6.44)6.39 (6.16, 6.58)6.58 (6.44, 6.76)< 0.001LAP32.99 (18.42, 63.37)26.32 (14.69, 57.32)54.78 (37.86, 72.30)62.71 (39.82, 86.89)0.001All‐cause mortalityYes28 (22.32%)13 (17.40%)6 (20.36%)9 (54.25%)0.012No134 (77.68%)103 (82.60%)20 (79.64%)11 (45.75%)Follow‐up time (months)37.00 (36.00, 84.00)82.42 (36.00, 84.00)37.00 (36.00, 84.00)36.00 (33.49, 37.49)0.017Abbreviations: ABSI, a body shape index; AISI, aggregate index of systemic inflammation; BMI, body mass index; CHARLS, China Health and Retirement Longitudinal Study; ConI, conicity index; CVAI, Chinese visceral adiposity index; FBG, fasting blood glucose; HDL, high density lipoprotein cholesterol; IQR, the interquartile range; LAP, lipid accumulation product; LDL, low density lipoprotein cholesterol; METS‐VF, metabolic score for visceral fat; TC, total cholesterol; TG, triglyceride; VAI, visceral adiposity index; WC, waist circumference. a Survey data were presented as weighted median (IQR) for continuous variables, and unweighted frequencies (weighted proportions) for categorical variables. Characteristics of cancer survivors in the CHARLS cohort according to different ABSI levels. Abbreviations: ABSI, a body shape index; AISI, aggregate index of systemic inflammation; BMI, body mass index; CHARLS, China Health and Retirement Longitudinal Study; ConI, conicity index; CVAI, Chinese visceral adiposity index; FBG, fasting blood glucose; HDL, high density lipoprotein cholesterol; IQR, the interquartile range; LAP, lipid accumulation product; LDL, low density lipoprotein cholesterol; METS‐VF, metabolic score for visceral fat; TC, total cholesterol; TG, triglyceride; VAI, visceral adiposity index; WC, waist circumference. Survey data were presented as weighted median (IQR) for continuous variables, and unweighted frequencies (weighted proportions) for categorical variables. In the NHANES cohort (Table 2), 1783 cancer survivors were included (weighted population: 8,556,033; weighted median age: 64 years). Analysis of the weighted NHANES data revealed significant differences across ABSI levels for most variables (p < 0.05), except for BMI, lymphocyte count, platelet count, and PLR. Higher ABSI values (ABSI_H; ABSI ≥ 8.87 × 10−2) were associated with older age (weighted median 75.00 [IQR 67.00, 80.00] years) compared to the lowest level (ABSI_L; ABSI ≤ 8.20 × 10−2; weighted median 54.00 [IQR 45.00, 66.00] years), as well as a greater prevalence of hypertension (weighted rate of 63.18% vs. 39.65%), hypercholesterolemia (weighted rate of 56.82% vs. 41.22%), and diabetes (weighted rate of 28.69% vs. 8.23%). Participants in the highest ABSI level were predominantly male (weighted rate of 55.68%), and smoking prevalence increased with ABSI (weighted rate of 59.60% in ABSI_H vs. 44.85% in ABSI_L). Furthermore, those with higher ABSI showed an increasing trend in visceral obesity indices (ConI, VAI, CVAI, METS‐VF, and LAP) and most blood test indicators (FBG, TG, neutrophils, monocytes, NLR, MLR, SIRI, SII, and AISI), while TC, HDL, and LDL decreased (all p < 0.05). In the CHARLS cohort (Table 3), 162 cancer survivors were included (weighted population: 5,631,233; weighted median age: 57.02 years). Similar to the NHANES cohort, higher ABSI was associated with older age, with a weighted median of 67.37 years (IQR 57.92, 72.10) in the ABSI_H level (ABSI ≥ 8.89 × 10−2) compared to 56.00 years (IQR 49.00, 64.00) in the ABSI_L level (ABSI ≤ 8.50 × 10−2). Notably, the prevalence of diabetes increased markedly across ABSI levels, rising from weighted rate of 9.65% in ABSI_L level to 38.74% in ABSI_H level. Participants with higher ABSI values also showed significantly elevated levels of visceral obesity indices, including ConI, VAI, CVAI, METS‐VF, and LAP, as well as blood test markers such as FBG and TG (all p < 0.05). Associations Between Six Visceral Obesity Indices, BMI, and All‐Cause Mortality During a weighted median follow‐up period of 85 months in the NHANES cohort, there were 554 deaths, representing a weighted mortality rate of 23.21% (Table 2). In comparison, the CHARLS study reported 28 deaths (weighted mortality rate of 22.32%) over a weighted median follow‐up of 37 months (Table 3). Weighted KM survival curves from the NHANES cohort indicated that cancer survivors with higher ABSI, ConI, CVAI, and METS‐VF values experienced significantly greater risks of all‐cause mortality (all Log‐rank p < 0.05; Figure 2A). In contrast, higher VAI, LAP, and BMI were not associated with increased mortality risk (all Log‐rank p > 0.05; Figure S3). Similar trends were observed in the unweighted survival curves of NHANES (Figure S4). In the CHARLS cohort, weighted KM survival analysis by ABSI levels also revealed a significant association with all‐cause mortality (Log‐rank p = 0.036; Figure 2B). However, other indices (CI, VAI, CVAI, METS‐VF, LAP, and BMI) did not show significant associations with mortality risk in this cohort (all Log‐rank p > 0.05; Figures S5 and S6). Weighted Kaplan–Meier curves for cancer survivors in the NHANES and CHARLS cohorts, highlighting indices with statistically significant differences post‐stratification. (A) Overall survival according to different levels of the ABSI, ConI, CVAI, and METS‐VF in the NHANES cohort; (B) Overall survival according to different levels of the ABSI in the CHARLS cohort. ABSI, a body shape index; ABSI_L, low level of ABSI; ABSI_M, median level of ABSI; ABSI_H, high level of ABSI; CHARLS, China Health and Retirement Longitudinal Study; ConI, conicity index; ConI_L, low level of ConI; ConI_M, median level of ConI; ConI_H, high level of ConI; CVAI, Chinese visceral adiposity index; CVAI_L, low level of CVAI; CVAI_M, median level of CVAI; CVAI_H, high level of CVAI; METS‐VF, metabolic score for visceral fat; METS‐VF_L, low level of METS‐VF; METS‐VF_M, median level of METS‐VF; METS‐VF_H, high level of METS‐VF; NHANES, National Health and Nutrition Examination Survey. Table 4 presents weighted Cox regression models analyzing the associations of six visceral obesity indices and BMI with all‐cause mortality among NHANES cancer survivors. In the unadjusted Model 1, each 1‐standard deviation (SD) increase in ABSI was linked to a 76% higher risk of all‐cause mortality (hazard ratio [HR] 1.76; 95% CI 1.56–1.98; p < 0.001); participants with the highest ABSI (ABSI_H) had a 427% higher mortality risk than those with the lowest ABSI (ABSI_L) (HR 5.27; 95% CI 3.77–7.36; p for trend < 0.001). After adjusting for sex and age (Model 2), the risk associated with each 1‐SD ABSI increase was attenuated but remained significant (HR 1.20; 95% CI 1.05–1.36; p = 0.008), and ABSI_H participants still had an 86% higher mortality risk than ABSI_L participants (HR 1.86; 95% CI 1.28–2.71; p for trend = 0.001). With further adjustments (Model 3), each 1‐SD ABSI increment was associated with a 14% higher risk (HR 1.14; 95% CI 1.00–1.29; p = 0.049), and ABSI_H was linked to a 71% higher risk than ABSI_L (HR 1.71; 95% CI 1.18–2.48; p for trend = 0.005). In both the fully adjusted Model 4 and the collinearity‐controlled Model 5 (Figures S7A and S8A), each 1‐SD ABSI increase and higher ABSI levels were associated with elevated mortality risk (all p < 0.05; all p for trend p < 0.05). Other indices showed varied results: ConI was significantly associated with mortality in Models 1 and 4 but lost significance in Model 5 after collinearity control (p = 0.159; Figures S7B and S8B); CVAI showed a significant association with mortality in Model 1 only, with no such significance in other models (Table 4; Figures S7D and S8D). Notably, higher METS‐VF was linked to a significantly lower risk of all‐cause mortality in Model 4 (HR 0.71 per 1‐SD increment; 95% CI 0.51–0.95; p = 0.024), yet this association became non‐significant in Model 5 after collinearity control (p = 0.343; Figures S7E and S8E). Additionally, VAI (Table 4; Figures S7C and S8C), LAP (Table 4; Figures S7F and S8F), and BMI (Table 4; Figures S7G and S8G) exhibited no significant associations with mortality across any model. TABLE 4Weighted multivariable Cox regression models analysis of the relationship between six visceral obesity indices, BMI, and all‐cause mortality among cancer survivors in the NHANES cohort.CharacteristicsModel 1Model 2Model 3Model 4Model 5HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p ABSI (Per 1‐SD increment)1.76 (1.56, 1.98)< 0.0011.20 (1.05, 1.36)0.0081.14 (1, 1.29)0.0491.91 (1.22, 2.97)0.0041.17 (1.02, 1.34)0.027ABSI levelsABSI_LReferenceReferenceReferenceReferenceReferenceABSI_M2.75 (2.06, 3.68)< 0.0011.46 (1.07, 1.99)0.0161.48 (1.08, 2.02)0.0142.09 (1.4–3.11)< 0.0011.54 (1.13, 2.11)0.007ABSI_H5.27 (3.77, 7.36)< 0.0011.86 (1.28, 2.71)0.0011.71 (1.18, 2.48)0.0053.07 (1.65–5.7)< 0.0011.80 (1.21, 2.67)0.004 p for trend< 0.0010.0010.004< 0.0010.004ConI (Per 1‐SD increment)1.49 (1.33, 1.66)< 0.0011.13 (0.99, 1.29)0.0661.06 (0.93, 1.2)0.4062.61 (1.2, 5.7)0.0161.11 (0.96, 1.28)0.159ConI levelsConI_LReferenceReferenceReferenceReferenceReferenceConI_M1.79 (1.36, 2.35)< 0.0011.11 (0.83, 1.48)0.4981.07 (0.81, 1.42)0.6201.29 (0.89, 1.87)0.1801.17 (0.88, 1.57)0.278ConI_H2.79 (2.07, 3.75)< 0.0011.37 (0.99, 1.91)0.0611.18 (0.84, 1.66)0.3281.63 (0.92, 2.9)0.0971.33 (0.93, 1.91)0.121 p for trend< 0.0010.0560.3220.0970.120VAI (Per 1‐SD increment)1.01 (0.9, 1.12)0.9071.02 (0.92, 1.13)0.6921.01 (0.91, 1.12)0.8351.06 (0.81, 1.39)0.6591.03 (0.9, 1.17)0.651VAI levelsVAI_LReferenceReferenceReferenceReferenceReferenceVAI_M0.87 (0.68, 1.11)0.2560.85 (0.67, 1.08)0.1770.81 (0.64, 1.02)0.0760.7 (0.51, 0.95)0.0220.71 (0.51, 0.97)0.032VAI_H0.9 (0.64, 1.27)0.5550.97 (0.69, 1.36)0.8620.97 (0.7, 1.35)0.8700.67 (0.38, 1.21)0.1860.7 (0.39, 1.25)0.226 p for trend0.4220.6020.5230.1550.193CVAI (Per 1‐SD increment)1.34 (1.22, 1.48)< 0.0011.02 (0.88, 1.18)0.8350.94 (0.8, 1.1)0.4511.46 (0.69, 3.08)0.3230.93 (0.79, 1.09)0.375CVAI levelsCVAI_LReferenceReferenceReferenceReferenceReferenceCVAI_M2.84 (1.81, 4.46)< 0.0011.14 (0.72, 1.81)0.5811.15 (0.74, 1.79)0.5321.24 (0.78, 1.98)0.3621.32 (0.83, 2.09)0.238CVAI_H3.55 (2.33, 5.4)< 0.0011.13 (0.69, 1.82)0.6331 (0.62, 1.6)0.9961.14 (0.63, 2.04)0.6651.27 (0.76, 2.14)0.366 p for trend< 0.0010.7660.5460.9850.617METS‐VF (Per 1‐SD increment)1.59 (1.4, 1.8)< 0.0011 (0.86, 1.16)0.9700.92 (0.79, 1.06)0.2520.71 (0.52, 0.95)0.0240.91 (0.75, 1.11)0.343METS‐VF levelsMETS‐VF_LReferenceReferenceReferenceReferenceReferenceMETS‐VF_M1.84 (1.47, 2.31)< 0.0011 (0.79, 1.27)0.9990.9 (0.7, 1.15)0.3900.81 (0.59, 1.11)0.1840.92 (0.69, 1.22)0.556METS‐VF_H3.19 (2.45, 4.14)< 0.0011.11 (0.82, 1.52)0.4930.88 (0.63, 1.24)0.4760.75 (0.47, 1.22)0.2460.92 (0.59, 1.44)0.726 p for trend< 0.0010.6300.4000.1890.627LAP (Per 1‐SD increment)1.01 (0.91, 1.13)0.8161.01 (0.9, 1.15)0.8140.98 (0.86, 1.12)0.7971.19 (0.76, 1.86)0.4451.03 (0.86, 1.22)0.756LAP levelsLAP_LReferenceReferenceReferenceReferenceReferenceLAP_M1.17 (0.9, 1.51)0.2510.95 (0.73, 1.24)0.7300.89 (0.67, 1.17)0.3870.75 (0.54, 1.05)0.0940.76 (0.54, 1.05)0.099LAP_H0.92 (0.7, 1.22)0.5740.91 (0.69, 1.2)0.4950.81 (0.61, 1.08)0.1530.57 (0.34, 0.94)0.0290.56 (0.33, 0.92)0.023 p for trend0.6140.4910.1510.0320.099BMI (Per 1‐SD increment)0.89 (0.8, 1)0.0590.98 (0.85, 1.13)0.7690.92 (0.79, 1.07)0.2700.84 (0.27, 2.65)0.7680.77 (0.56, 1.07)0.116BMI levelsBMI_LReferenceReferenceReferenceReferenceReferenceBMI_M0.88 (0.68, 1.14)0.3310.76 (0.61, 0.95)0.0180.7 (0.55, 0.89)0.0040.61 (0.45, 0.83)0.0010.64 (0.48, 0.85)0.002BMI_H0.72 (0.53, 0.99)0.0410.91 (0.67, 1.24)0.5500.77 (0.56, 1.06)0.1080.63 (0.36, 1.09)0.1000.65 (0.37, 1.12)0.119 p for trend0.0410.5290.1230.1180.128 Note: Model 1: No covariates were adjusted for; Model 2: Adjusted for age and sex; Model 3: Adjusted for age, sex, education level, smoking, hypertension, hypercholesterolemia, diabetes, and cancer type; Model 4: Adjusted for age, sex, education level, smoking, hypertension, hypercholesterolemia, diabetes, cancer type, height, weight, WC, FBG, TC, HDL, LDL, and TG; Model 5: Adjusted for the variables with a variance inflation factor less than 10 in Model 4.Abbreviations: ABSI, a body shape index; ABSI_H, ABSI ≥ 8.87 × 10−2; ABSI_L, ABSI ≤ 8.20 × 10−2; ABSI_M, 8.20 × 10−2 < ABSI < 8.87 × 10−2; BMI, body mass index; BMI_H, BMI ≥ 31.65 kg/m2; BMI_L, BMI ≤ 25.27 kg/m2; BMI_M, 25.27 kg/m2 < BMI < 31.65 kg/m2; CI, confidence interval; ConI, conicity index; ConI_H, ConI ≥ 1.40; ConI_L, ConI ≤ 1.31; ConI_M, 1.31 < ConI < 1.40; CVAI, Chinese visceral adiposity index; CVAI_H, CVAI ≥ 163.72; CVAI_L, CVAI ≤ 98.74; CVAI_M, 98.74 < CVAI < 163.72; FBG, fasting blood glucose; HDL, high density lipoprotein cholesterol; HR, hazard ratio; LAP, lipid accumulation product; LAP_H, LAP ≥ 79.60; LAP_L, LAP ≤ 49.00; LAP_M, 49.00 < LAP < 79.60; LDL, low density lipoprotein cholesterol; METS‐VF, metabolic score for visceral fat; METS‐VF_H, METS‐VF ≥ 6.98; METS‐VF_L, METS‐VF ≤ 6.55; METS‐VF_M, 6.55 < METS‐VF < 6.98; NHANES, National Health and Nutrition Examination Survey; SD, standard deviation; TC, total cholesterol; TG, triglyceride; VAI, visceral adiposity index; VAI_H, VAI ≥ 3.63; VAI_L, VAI ≤ 2.01; VAI_M, 2.01 < VAI < 3.63; WC, waist circumference. Weighted multivariable Cox regression models analysis of the relationship between six visceral obesity indices, BMI, and all‐cause mortality among cancer survivors in the NHANES cohort. Note: Model 1: No covariates were adjusted for; Model 2: Adjusted for age and sex; Model 3: Adjusted for age, sex, education level, smoking, hypertension, hypercholesterolemia, diabetes, and cancer type; Model 4: Adjusted for age, sex, education level, smoking, hypertension, hypercholesterolemia, diabetes, cancer type, height, weight, WC, FBG, TC, HDL, LDL, and TG; Model 5: Adjusted for the variables with a variance inflation factor less than 10 in Model 4. Abbreviations: ABSI, a body shape index; ABSI_H, ABSI ≥ 8.87 × 10−2; ABSI_L, ABSI ≤ 8.20 × 10−2; ABSI_M, 8.20 × 10−2 < ABSI < 8.87 × 10−2; BMI, body mass index; BMI_H, BMI ≥ 31.65 kg/m2; BMI_L, BMI ≤ 25.27 kg/m2; BMI_M, 25.27 kg/m2 < BMI < 31.65 kg/m2; CI, confidence interval; ConI, conicity index; ConI_H, ConI ≥ 1.40; ConI_L, ConI ≤ 1.31; ConI_M, 1.31 < ConI < 1.40; CVAI, Chinese visceral adiposity index; CVAI_H, CVAI ≥ 163.72; CVAI_L, CVAI ≤ 98.74; CVAI_M, 98.74 < CVAI < 163.72; FBG, fasting blood glucose; HDL, high density lipoprotein cholesterol; HR, hazard ratio; LAP, lipid accumulation product; LAP_H, LAP ≥ 79.60; LAP_L, LAP ≤ 49.00; LAP_M, 49.00 < LAP < 79.60; LDL, low density lipoprotein cholesterol; METS‐VF, metabolic score for visceral fat; METS‐VF_H, METS‐VF ≥ 6.98; METS‐VF_L, METS‐VF ≤ 6.55; METS‐VF_M, 6.55 < METS‐VF < 6.98; NHANES, National Health and Nutrition Examination Survey; SD, standard deviation; TC, total cholesterol; TG, triglyceride; VAI, visceral adiposity index; VAI_H, VAI ≥ 3.63; VAI_L, VAI ≤ 2.01; VAI_M, 2.01 < VAI < 3.63; WC, waist circumference. Table 5 presents the Cox regression results for the CHARLS cohort. Consistent with the findings from the NHANES cohort, ABSI exhibited a robust association with all‐cause mortality: each 1‐SD increase in ABSI was significantly linked to a higher risk of all‐cause mortality across all five models (all p < 0.05). Similarly, when analyzed by ABSI levels, participants with higher ABSI showed a significantly elevated mortality risk in all models, with significant trends observed in each (all p for trend < 0.05; Figures S9A and S10A). For other indices, the associations were less consistent. A 1‐SD increase in ConI was significantly associated with mortality in Models 3 and 4 (all p < 0.05) but not in Models 1, 2, and 5 (Figures S9B and S10B). VAI showed significant associations with mortality per 1‐SD increase in Models 1–3 and 5 (all p < 0.05; Figures S9C and S10C); however, when VAI was categorized into levels, this association no longer reached statistical significance (Table 5; Figures S9C and S10C). No other visceral obesity indices, including CVAI (Table 5; Figures S9D and S10D), METS‐VF (Table 5; Figures S9E and S10E), LAP (Table 5; Figures S9F and S10F), and BMI (Table 5; Figures S9G and S10G), demonstrated significant associations with all‐cause mortality in the CHARLS cohort. TABLE 5Weighted multivariable Cox regression models analysis of the relationship between six visceral obesity indices, BMI, and all‐cause mortality among cancer survivors in the CHARLS cohort.CharacteristicsModel 1Model 2Model 3Model 4Model 5HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p ASBI (Per 1‐SD increment)1.52 (1.09, 2.12)0.0141.46 (1.05, 2.04)0.0251.8 (1.15, 2.79)0.0099.89 (1.27, 76.9)0.0291.55 (1.01, 2.39)0.046ASBI levelsASBI‐LReferenceReferenceReferenceReferenceReferenceASBI‐M1.26 (0.41, 3.85)0.681.39 (0.43, 4.51)0.5792.31 (0.81, 6.62)0.1192.89 (0.65, 12.9)0.1642.17 (0.64, 7.41)0.216ASBI‐H5.59 (2.56, 12.18)< 0.0015.74 (2.44, 13.52)< 0.0019.51 (4.04, 22.38)< 0.00120.46 (3.07, 136.23)0.0027.66 (2.78, 21.09)< 0.001 p for trend< 0.0010.001< 0.0010.001< 0.001ConI (Per 1‐SD increment)1.37 (0.92–2.05)0.1191.34 (0.93–1.93)0.1171.62 (1.06, 2.46)0.02568.56 (2.3, 2042.57)0.0151.8 (0.97, 3.36)0.063ConI levelsConI‐LReferenceReferenceReferenceReferenceReferenceConI‐M1.22 (0.33, 4.51)0.7671.27 (0.33, 4.9)0.7281.74 (0.66, 4.62)0.2652.57 (0.61, 10.85)0.1982.03 (0.7, 5.93)0.193ConI‐H4.67 (1.91, 11.41)0.0015.68 (2.19, 14.74)< 0.00110.69 (3.48, 32.81)< 0.00129.56 (3.96, 220.81)0.00113.65 (3.53, 52.77)< 0.001 p for trend0.0170.019< 0.0010.002< 0.001VAI (Per 1‐SD increment)1.58 (1.3, 1.92)< 0.0011.58 (1.27, 1.98)< 0.0011.69 (1.34, 2.13)< 0.0011.35 (0.68, 2.69)0.3891.74 (1.39, 2.16)< 0.001VAI levelsVAI‐LReferenceReferenceReferenceReferenceReferenceVAI‐M0.65 (0.24, 1.75)0.3910.86 (0.18, 4.18)0.8500.96 (0.15, 6.29)0.9661.28 (0.17, 9.44)0.8060.79 (0.18, 3.51)0.760VAI‐H0.77 (0.26, 2.27)0.6330.99 (0.22, 4.5)0.9901.37 (0.25, 7.46)0.7191.48 (0.14, 15.51)0.7421.21 (0.3, 4.94)0.786 p for trend0.7450.9700.6430.7560.712CVAI (Per 1‐SD increment)1.09 (0.66, 1.79)0.7410.99 (0.6, 1.64)0.9661.04 (0.64, 1.71)0.8710.7 (0.08, 5.96)0.7450.91 (0.54, 1.56)0.738CVAI levelsCVAI‐LReferenceReferenceReferenceReferenceReferenceCVAI‐M1.31 (0.42, 4.03)0.6431.06 (0.4, 2.84)0.9021.06 (0.44, 2.57)0.8901.72 (0.6, 4.95)0.3120.95 (0.45, 2.01)0.896CVAI‐H2.22 (0.67, 7.36)0.1911.68 (0.5, 5.69)0.4032.57 (0.63, 10.47)0.18711.99 (0.91, 157.33)0.0593.26 (0.5, 21.03)0.215 p for trend0.2570.5010.3420.0860.401METS‐VF (Per 1‐SD increment)1.23 (0.64, 2.34)0.5361.08 (0.66, 1.78)0.7551.12 (0.68, 1.85)0.6490.89 (0.32, 2.5)0.8301.06 (0.62, 1.82)0.826METS‐VF levelsMETS‐VF‐LReferenceReferenceReferenceReferenceReferenceMETS‐VF‐M0.74 (0.2, 2.7)0.6520.55 (0.14, 2.08)0.3750.48 (0.13, 1.82)0.2811.23 (0.24, 6.31)0.8050.41 (0.11, 1.6)0.202METS‐VF‐H2.57 (0.82, 8.06)0.1061.89 (0.71, 5.05)0.2032.45 (0.94, 6.36)0.0669.54 (1.61, 56.46)0.0132.92 (1.13, 7.51)0.026 p for trend0.1580.2410.1090.0240.062LAP (Per 1‐SD increment)0.95 (0.63, 1.45)0.8210.99 (0.63, 1.54)0.9551.03 (0.7, 1.53)0.8650.17 (0.02, 1.2)0.0751.15 (0.71, 1.87)0.577LAP levelsLAP‐LReferenceReferenceReferenceReferenceReferenceLAP‐M1.07 (0.36, 3.22)0.8981.22 (0.32, 4.62)0.7721.29 (0.42, 3.95)0.6522 (0.62, 6.5)0.2461.32 (0.39, 4.48)0.658LAP‐H1.93 (0.54, 6.87)0.3071.81 (0.44, 7.47)0.4152.1 (0.53, 8.28)0.28713.59 (0.36, 516.23)0.1603.13 (0.5, 19.46)0.222 p for trend0.3560.4230.2940.1640.658BMI (Per 1‐SD increment)0.83 (0.57, 1.22)0.3490.91 (0.58, 1.44)0.6900.91 (0.58, 1.43)0.6870.59 (0.01, 45.75)0.8150.38 (0.12, 1.18)0.094BMI levelsBMI‐LReferenceReferenceReferenceReferenceReferenceBMI‐M1.13 (0.5, 2.55)0.7631.39 (0.47, 4.12)0.5581.14 (0.49, 2.66)0.7540.67 (0.12, 3.76)0.6490.95 (0.43, 2.07)0.889BMI‐H0.39 (0.13, 1.19)0.0990.49 (0.12, 2.03)0.3280.55 (0.14, 2.1)0.3790.29 (0.01, 6.72)0.4410.45 (0.13, 1.61)0.221 p for trend0.1450.5310.4910.4730.235 Note: Model 1: No covariates were adjusted for; Model 2: Adjusted for age and sex; Model 3: Adjusted for age, sex, education level, smoking, hypertension, hypercholesterolemia, and diabetes; Model 4: Adjusted for age, sex, education level, smoking, hypertension, hypercholesterolemia, diabetes, height, weight, WC, FBG, TC, HDL, LDL, and TG; Model 5: Adjusted for the variables with a variance inflation factor less than 10 in Model 4.Abbreviations: ABSI, a body shape index; ABSI_H, ABSI ≥ 8.89 × 10−2; ABSI_L, ABSI ≤ 8.50 × 10−2; ABSI_M, 8.50 × 10−2 < ABSI < 8.89 × 10−2; BMI, body mass index; BMI_H, BMI ≥ 26.44 kg/m2; BMI_L, BMI ≤ 23.46 kg/m2; BMI_M, 23.46 kg/m2 < BMI < 26.44 kg/m2; CHARLS, China Health and Retirement Longitudinal Study; CI, confidence interval; ConI, conicity index; ConI_H, ConI ≥ 1.39; ConI_L, ConI ≤ 1.32; ConI_M, 1.32 < ConI < 1.39; CVAI, Chinese visceral adiposity index; CVAI_H, CVAI ≥ 152.63; CVAI_L, CVAI ≤ 86.84; CVAI_M, 86.84 < CVAI < 152.63; FBG, fasting blood glucose; HDL, high density lipoprotein cholesterol; HR, hazard ratio; LAP, lipid accumulation product; LAP_H, LAP ≥ 100.89; LAP_L, LAP ≤ 25.12; LAP_M, 25.12 < LAP < 100.89; LDL, low density lipoprotein cholesterol; METS‐VF, metabolic score for visceral fat; METS‐VF_H, METS‐VF ≥ 6.43; METS‐VF_L, METS‐VF ≤ 6.18; METS‐VF_M, 6.18 < METS‐VF < 6.43; SD, standard deviation; TC, total cholesterol; TG, triglyceride; VAI, visceral adiposity index; VAI_H, VAI ≥ 2.33; VAI_L, VAI ≤ 1.15; VAI_M, 1.15 < VAI < 2.33; WC, waist circumference. Weighted multivariable Cox regression models analysis of the relationship between six visceral obesity indices, BMI, and all‐cause mortality among cancer survivors in the CHARLS cohort. Note: Model 1: No covariates were adjusted for; Model 2: Adjusted for age and sex; Model 3: Adjusted for age, sex, education level, smoking, hypertension, hypercholesterolemia, and diabetes; Model 4: Adjusted for age, sex, education level, smoking, hypertension, hypercholesterolemia, diabetes, height, weight, WC, FBG, TC, HDL, LDL, and TG; Model 5: Adjusted for the variables with a variance inflation factor less than 10 in Model 4. Abbreviations: ABSI, a body shape index; ABSI_H, ABSI ≥ 8.89 × 10−2; ABSI_L, ABSI ≤ 8.50 × 10−2; ABSI_M, 8.50 × 10−2 < ABSI < 8.89 × 10−2; BMI, body mass index; BMI_H, BMI ≥ 26.44 kg/m2; BMI_L, BMI ≤ 23.46 kg/m2; BMI_M, 23.46 kg/m2 < BMI < 26.44 kg/m2; CHARLS, China Health and Retirement Longitudinal Study; CI, confidence interval; ConI, conicity index; ConI_H, ConI ≥ 1.39; ConI_L, ConI ≤ 1.32; ConI_M, 1.32 < ConI < 1.39; CVAI, Chinese visceral adiposity index; CVAI_H, CVAI ≥ 152.63; CVAI_L, CVAI ≤ 86.84; CVAI_M, 86.84 < CVAI < 152.63; FBG, fasting blood glucose; HDL, high density lipoprotein cholesterol; HR, hazard ratio; LAP, lipid accumulation product; LAP_H, LAP ≥ 100.89; LAP_L, LAP ≤ 25.12; LAP_M, 25.12 < LAP < 100.89; LDL, low density lipoprotein cholesterol; METS‐VF, metabolic score for visceral fat; METS‐VF_H, METS‐VF ≥ 6.43; METS‐VF_L, METS‐VF ≤ 6.18; METS‐VF_M, 6.18 < METS‐VF < 6.43; SD, standard deviation; TC, total cholesterol; TG, triglyceride; VAI, visceral adiposity index; VAI_H, VAI ≥ 2.33; VAI_L, VAI ≤ 1.15; VAI_M, 1.15 < VAI < 2.33; WC, waist circumference. Analyses of Trends Between Six Visceral Obesity Indices, BMI, and All‐Cause Mortality Among Cancer Survivors To flexibly explore and visualize the associations between six visceral obesity indices, BMI, and all‐cause mortality among cancer survivors, we employed RCS models. In the NHANES cohort, RCS analyses revealed a significant and approximately linear association between ABSI and all‐cause mortality across all five models (p for overall < 0.05; p for nonlinear > 0.05; Figure 3A). Consistent trends were observed in the CHARLS cohort: in Models 1–3, ABSI also exhibited a significant and approximately linear correlation with all‐cause mortality (p for overall < 0.05; p for nonlinear > 0.05; Figure 3B). Notably, in Model 4, the overall association between ABSI and all‐cause mortality in the CHARLS cohort lost statistical significance; however, after collinearity correction was applied, the association regained significance and remained approximately linear in Model 5 (p for overall < 0.05; p for nonlinear > 0.05; Figure 3B). In contrast, no other indices (including the other five visceral obesity indices and BMI) showed a consistently linear relationship with survival outcomes across the two cohorts (Figures S10–S16). Restricted cubic spline of the linear trends between ABSI with all‐cause mortality of the cancer survivors. (A) All‐cause mortality risk with different levels of the ABSI in the NHANES cohort adjusted by Models 1–5; (B) All‐cause mortality risk with different levels of the ABSI in the CHARLS cohort adjusted by Models 1–5. Model 1: No covariates were adjusted for; Model 2: Adjusted for age and sex; Model 3: Further adjusted for education level, smoking, hypertension, hypercholesterolemia, diabetes, and cancer type (note: Cancer type stratification was not applicable to the CHARLS cohort); Model 4: Additionally adjusted for height, weight, WC, FBG, TC, HDL, LDL, and TG; Model 5: Adjusted the variables in Model 4 with a VIF less than 10 because a VIF greater than 10 indicates a high degree of multicollinearity among variables. ABSI, a body shape index; CHARLS, China Health and Retirement Longitudinal Study; CI, confidence interval; FBG, fasting blood glucose; HDL, high‐density lipoprotein cholesterol; HR, hazard ratio; LDL, low‐density lipoprotein cholesterol; NHANES, National Health and Nutrition Examination Survey; TC, total cholesterol; TG, triglyceride; VIF, variance inflation factor; WC, waist circumference. Mediating Role of Inflammatory Biomarkers Multivariate Cox regression analyses identified ABSI as a potential independent risk factor for all‐cause mortality among cancer survivors in both the NHANES and CHARLS cohorts, outperforming other obesity indices. To investigate potential mechanisms underlying this relationship, we conducted a mediation analysis in the NHANES cohort. The results showed that several inflammatory biomarkers, including neutrophils, NLR, SIRI, SII, and AISI, significantly mediated the association between ABSI and all‐cause mortality (Table 6). Among all tested biomarkers, neutrophils exhibited a significant mediation effect on the ABSI‐mortality association, with the highest mediation proportion of 16.77% (95% CI: 6.30%–41.80%, p = 0.002). TABLE 6Mediation analysis of the impact of inflammatory biomarkers on the relationship between ABSI and all‐cause mortality in the NHANES cohort.Inflammatory biomarkersTotal effectIndirect effectDirect effectProportion mediatedHR (95% CI) p HR (95% CI) p HR (95% CI) p Proportion (95% CI) p Neutrophils1.19 (1.07, 1.33)0.0021.03 (1.01, 1.05)< 0.0011.16 (1.04, 1.29)0.00816.77% (6.30%, 41.80%)0.002Lymphocyte1.18 (1.06, 1.31)0.0021.00 (1.00, 1.00)0.6921.18 (1.06, 1.32)0.002−0.28% (−3.10%, 1.90%)0.694Platelet1.17 (1.05, 1.31)0.0061.00 (0.99, 1.01)0.8501.17 (1.05, 1.31)0.006−0.41% (−7.41%, 4.70%)0.852Monocyte1.18 (1.06, 1.32)0.0021.00 (1.00, 1.01)0.6521.18 (1.06, 1.32)0.0021.00% (−3.74%, 8.00%)0.654NLR1.18 (1.07, 1.33)0.0021.01 (1.00, 1.03)0.0041.17 (1.05, 1.31)0.0067.94% (2.49%, 24.20%)0.006PLR1.17 (1.06, 1.31)0.0041.00 (0.99, 1.01)0.7941.17 (1.06, 1.31)0.004−0.55% (−7.05%, 4.50%)0.798MLR1.18 (1.07, 1.33)0.0021.00 (1.00, 1.01)0.2821.18 (1.06, 1.32)0.0022.85% (−2.61%, 10.20%)0.284SIRI1.18 (1.07, 1.33)0.0021.01 (1.00, 1.04)< 0.0011.17 (1.05, 1.31)0.0048.62% (2.98%, 25.90%)0.002SII1.18 (1.06, 1.32)0.0041.01 (1.00, 1.03)0.0041.16 (1.04, 1.29)0.0069.07% (2.34%, 26.30%)0.008AISI1.18 (1.06, 1.32)0.0021.02 (1.01, 1.04)0.0021.16 (1.05, 1.29)0.00811.68% (4.04%, 33.80%)0.004Abbreviations: ABSI, a body shape index; AISI, aggregate index of systemic inflammation; CI, confidence interval; HR, hazard ratio; MLR, monocyte/lymphocyte ratio; NHANES, National Health and Nutrition Examination Survey; NLR, neutrophil/lymphocyte ratio; PLR, platelet/lymphocyte ratio; SII, systemic inflammation index; SIRI, systemic inflammation response index. Mediation analysis of the impact of inflammatory biomarkers on the relationship between ABSI and all‐cause mortality in the NHANES cohort. Abbreviations: ABSI, a body shape index; AISI, aggregate index of systemic inflammation; CI, confidence interval; HR, hazard ratio; MLR, monocyte/lymphocyte ratio; NHANES, National Health and Nutrition Examination Survey; NLR, neutrophil/lymphocyte ratio; PLR, platelet/lymphocyte ratio; SII, systemic inflammation index; SIRI, systemic inflammation response index. Subgroup Analyses Table S1 presents the results of subgroup analyses, which were stratified by cancer type, sex, educational level, smoking status, and the presence of hypertension, hypercholesterolemia, or diabetes in the NHANES and CHARLS cohorts (note: cancer type stratification was not applicable to the CHARLS cohort). Except for hypertension in the CHARLS cohort, no significant interactions were observed between other variables and ABSI with respect to all‐cause mortality (all P for interaction > 0.05). This indicates that the impact of ABSI on all‐cause mortality is consistent across different demographic and clinical subgroups. Sensitivity Analyses and Potential for Unmeasured Confounding To validate the robustness of our findings, we performed three sensitivity analyses, with results consistent with the primary conclusions as follows: First, we re‐imputed missing values using a random forest algorithm and re‐conducted the analyses. The results were consistent with our primary analyses: across both the NHANES cohort (Tables S2–S4) and the CHARLS cohort (Tables S5 and S6), only ABSI remained significantly and independently associated with an increased risk of all‐cause mortality. Additionally, mediation analysis in the NHANES cohort (after missing value imputation) confirmed that neutrophils significantly mediated the association between ABSI and all‐cause mortality (Table S7). Second, to enhance cross‐cohort comparability, we applied the same ABSI cutoff values used in the NHANES cohort to the CHARLS cohort and performed weighted multivariable Cox regression analyses. The results showed that, even with uniform cutoff values, participants in the highest ABSI category had a significantly higher mortality risk than those in the lowest category (Table S8). Consistent with findings from X‐tile‐derived cutoffs, quartile‐based categorization of ABSI revealed a significant dose–response association with all‐cause mortality in both NHANES and CHARLS cohorts (all p for trend in the Model 5 < 0.05; Tables S9 and S10). Third, we additionally included participants with a follow‐up duration of 0 to 6 months based on the primary analysis. Both weighted and unweighted Kaplan–Meier analyses revealed that cancer survivors with higher ABSI values had a significantly elevated risk of all‐cause mortality in both cohorts (all Log‐rank p < 0.05; Figure S17). Weighted multivariable Cox regression analyses further demonstrated that participants in the highest ABSI category had a significantly higher mortality risk compared with those in the lowest category (all p for trend < 0.05; Table S11). Finally, we calculated E‐values to evaluate the potential impact of unmeasured confounding on the observed associations, specifically focusing on the association between ABSI and all‐cause mortality, as well as the indirect effect identified in the mediation analysis (Table S12). For the association between ABSI and all‐cause mortality, the E‐values for the hazard ratios (HRs) across the two cohorts ranged from 1.54 to 40.50. This indicates that an unmeasured confounder would need to be associated with both ABSI and all‐cause mortality by at least a 1.54‐fold risk ratio (independent of measured confounders) to fully explain the observed association, suggesting that the direct association is relatively robust to residual confounding. Notably, for the indirect effect of neutrophils in the mediation analysis, the E‐value was 1.21. While theoretically allowing for some unmeasured confounding, the required threshold (a 1.2‐fold association with ABSI, neutrophils, and mortality beyond measured factors) is modest. Discussion Key Study Findings In this nationally representative cohort study of cancer survivors, we found that among six visceral obesity indices and BMI, only ABSI demonstrated a significant and potential independent association with increased all‐cause mortality both in the NHANES and CHARLS database. Our findings highlight a positive, linear relationship between ABSI and mortality risk and suggest that inflammation, as measured by neutrophil, partially mediates this association. In contrast, BMI, a widely used but non‐visceral obesity index, showed no significant association with mortality in either database. Subgroup analyses across different demographic and clinical characteristics, as well as multiple sensitivity analyses, further supported the robustness of our findings. These results underscore the prognostic value of ABSI in survivorship care and suggest that assessments focusing on body shape and central adiposity may better capture mortality risk than traditional measures. ABSI Versus BMI: Advantages in Capturing Adiposity‐Related Risk in Cancer Survivors A key innovation of our study lies in clarifying ABSI's unique advantages over BMI in the context of cancer survivorship, a population with distinct body composition dynamics. Unlike BMI, which merely quantifies overall body mass and fails to differentiate between fat and lean mass or capture fat distribution [26, 27], ABSI incorporates waist circumference adjusted for height and weight, thereby reflecting visceral fat accumulation more accurately. This distinction is critical for cancer survivors: their body composition often undergoes marked changes due to cancer cachexia, treatment effects, and aging processes, which can render BMI an unreliable indicator of adiposity‐related health risks [28, 29]. For instance, a survivor may have a “normal” BMI but harbor excess visceral fat, a scenario BMI cannot detect, but ABSI can capture by accounting for body shape. Our data confirm this practical value: while BMI showed no association with mortality in either cohort, ABSI maintained a consistent, significant link across models, validating its ability to identify high‐risk individuals overlooked by BMI. Additionally, ABSI avoids the “obesity paradox” that often complicates BMI interpretation in clinical populations. Instead, as shown in previous research and corroborated by our findings, ABSI exhibits a linear correlation with visceral fat content and all‐cause mortality risk, making its clinical interpretation more straightforward [30, 31]. In cancer survivors, who face dual risks of cancer progression and cardiovascular comorbidities, this linearity is particularly valuable: it allows for clear risk stratification, whereas BMI's ambiguous relationship with outcomes limits its utility [32]. By extending these observations to cancer survivors, we provide evidence that ABSI addresses a critical gap in clinical practice, offering a more precise tool to assess mortality risk than the widely used but blunt BMI. Biological Mechanism: Neutrophil‐Mediated Partial Mediation of the ABSI‐Mortality Association The observed partial mediation of the ABSI‐mortality association by neutrophil count in our analysis provides insight into potential correlative biological mechanisms. As essential components of the innate immune system, neutrophils are pivotal mediators of inflammation, and their roles have been increasingly implicated in both cancer progression such as tumor growth, angiogenesis, and metastasis and systemic metabolic dysregulation such as insulin resistance and dyslipidemia [33, 34]. This dual involvement positions them as plausible intermediaries linking body shape indices like ABSI to adverse outcomes in cancer survivors. Visceral adiposity whose accumulation is effectively captured by ABSI is known to promote a chronic inflammatory state characterized by elevated circulating immune cells, including neutrophils [35]. Under the influence of pro‐inflammatory signals from visceral fat depots, neutrophils are recruited and activated, and they subsequently secrete pro‐inflammatory cytokines such as IL‐1β, TNF‐α, reactive oxygen species, and neutrophil extracellular traps [36, 37]. These substances can induce DNA damage, disrupt normal tissue architecture, and promote cellular transformation, collectively contributing to tissue damage and tumorigenesis, processes that may directly exacerbate mortality risk in cancer survivors [36]. This low‐grade, persistent inflammation driven by excess visceral fat further exacerbates cancer progression through multiple pathways: it fosters a tumor‐promoting microenvironment rich in growth factors and proteases, while also impairing immune surveillance mechanisms that normally keep residual cancer cells in check [38]. Moreover, the interaction between neutrophils and other immune cells, modulated by visceral adiposity, amplifies these adverse effects. Visceral fat‐derived cytokines first skew the balance of immune cell populations, promoting the recruitment of pro‐inflammatory monocytes and suppressing the activity of antitumor lymphocytes [8, 39]. Neutrophils then further amplify this imbalance by secreting factors that inhibit T‐cell proliferation and function, ultimately creating an immunosuppressive environment that allows cancer cells to evade detection and elimination [40]. This cascade, initiated by the visceral fat accumulation reflected in higher ABSI, may thus explain why neutrophil count partially mediates the association with mortality. Why Other Visceral Obesity Indices Failed to Predict Mortality in Cancer Survivors Interestingly, in our study, other visceral obesity indices beyond ABSI, including ConI, VAI, CVAI, METS‐VF, and LAP, did not show significant associations with all‐cause mortality among cancer survivors across both cohorts simultaneously. This finding contrasts with previous research where these indices have been widely validated as reliable predictors of cardiometabolic risk in the general population [41, 42]. Specifically, ConI, which estimates central adiposity by relating waist circumference to weight and height [43], did not demonstrate a significant association with mortality risk in our cancer survivor cohorts. A key reason is that although ConI captures abdominal fat distribution, its formula relies on a relatively simple anthropometric ratio. This may not account for the complex alterations in visceral fat quality or metabolic activity common in cancer survivors such as treatment‐induced muscle loss, shifts in fat‐to‐lean mass ratio, or localized adipose tissue dysfunction. In contrast, ABSI adjusts waist circumference for height and weight through a nonlinear calculation. This better captures subtle variations in body shape and fat distribution, allowing ABSI to remain sensitive to clinically relevant changes in visceral adiposity even amid the body composition perturbations typical of cancer survivors, a capability ConI lacks. Indices like VAI, CVAI, METS‐VF, and LAP face additional challenges. Unlike ABSI, VAI, CVAI, METS‐VF, and LAP all incorporate biochemical markers, most notably triglycerides (TG) and high‐density lipoprotein cholesterol (HDL), as core components of their calculation. This reliance on lab‐based parameters becomes problematic in cancer survivors, who frequently experience substantial metabolic disruptions driven by the disease itself or its treatments, including chemotherapy, radiation therapy, and hormonal therapies [44, 45]. These can alter lipid levels, inflammation status, and adipose tissue metabolism independently of visceral adiposity. Such disruptions decouple the biochemical markers in these indices from actual adiposity‐related risk, obscuring their predictive value. Notably, unlike these indices, which rely on lab‐based biochemical parameters and thus are prone to interference from post‐treatment metabolic alterations like chemotherapy‐induced dyslipidemia or steroid‐related glucose fluctuations, ABSI depends solely on anthropometric measures including waist circumference, height, and weight. These are less prone to short‐term fluctuations caused by cancer or its treatments [46]. This stability, combined with its ability to capture deviations from expected body shape, allows ABSI to more effectively reflect the adverse aspects of visceral adiposity linked to mortality risk in this population. This ultimately explains why it, unlike other indices, shows consistent and significant associations with outcomes across our cohorts. Clinical and Public Health Implications Our findings offer preliminary research insights with tentative clinical and public health relevance. Incorporating ABSI into routine survivorship assessments could potentially enhance risk stratification: for instance, if cancer survivors have an ABSI ≥ 8.87 × 10−2, targeted interventions to reduce visceral adiposity might contribute to improved survival outcomes. Such interventions include lifestyle modifications like diet and physical activity, which have been shown to lower visceral fat and inflammation [47]. Compared to BMI, ABSI's ability to identify “hidden” visceral adiposity in survivors with normal BMI could also help public health initiatives better allocate resources, focusing on individuals at true survival risk rather than relying on BMI cutoffs that may misclassify many survivors. Monitoring ABSI may further enable timely identification of high‐risk survivors who could benefit from more intensive follow‐up. Comparison With Previous Studies A critical comparison of our findings with previous studies highlights both consistencies and novel insights, further contextualizing the prognostic value of visceral obesity indices in cancer survivors. Regarding ABSI, our results align with prior research conducted in general populations and patients with cardiovascular diseases, which consistently demonstrated that ABSI is a superior predictor of all‐cause mortality compared to BMI, exhibits a linear association with mortality risk, and avoids the “obesity paradox” [30, 31, 48, 49, 50, 51]. However, our study extends these observations by confirming ABSI's potential independent prognostic value specifically in cancer survivors, a population with distinct body composition alterations, thus validating ABSI's generalizability beyond non‐cancer populations. In contrast to ABSI, our finding that BMI shows no significant association with mortality in cancer is consistent with prior tumor‐related studies [52, 53, 54], which have repeatedly emphasized BMI's limitations in this population due to its inability to distinguish fat from lean mass and its from actual adiposity risk amid cancer‐related body composition changes [21]. Notably, our results differ from previous research in general and cardiometabolic disease populations, where ConI, VAI, CVAI, METS‐VF, and LAP have been validated as reliable predictors of adverse outcomes [41, 42, 55, 56, 57, 58]. In our cancer survivor cohorts, none of these indices showed consistent significant associations with all‐cause mortality. This discrepancy is attributed to the unique physiological characteristics of cancer survivors: treatment‐induced metabolic disruptions decouple biochemical parameters (such as triglycerides and HDL cholesterol, which are incorporated into VAI, CVAI, METS‐VF, and LAP) from visceral adiposity risk [45], while ConI's simple anthropometric ratio fails to adapt to complex changes in body composition [59, 60]. Regarding the biological mechanism, our finding that neutrophil count partially mediates the ABSI‐mortality association complements prior studies linking visceral adiposity, chronic inflammation, and cancer progression [35], which have implicated neutrophils as key mediators of inflammation‐driven tumorigenesis but lacked direct evidence of their role in the association between body shape indices and cancer survivor mortality. Strengths and Limitations of the Study This study has several strengths, including the use of two large, nationally representative cohorts from different countries and comprehensive mortality ascertainment. Nonetheless, it is subject to limitations. First, as a re‐analysis of two existing cohorts (NHANES and CHARLS), inherent differences in their design and implementation may cause data measurement heterogeneity, limiting direct comparability of results between populations. However, the consistent association between ABSI and survival across cohorts, despite potential methodological heterogeneities, indicates the association may be stable in cancer survivor populations. This suggests ABSI's predictive value is not overly dependent on specific protocols or population backgrounds, supporting the generalizability of our core finding. Second, several inherent limitations stem from the constraints of the two public databases. Essential cancer‐specific variables including tumor stage, treatment modalities, time since diagnosis, and recurrence status were unavailable, which may introduce residual confounding. Cancer survivors were defined broadly based solely on self‐reported lifetime cancer history, with no detailed records of disease activity, remission status, or disease progression, thereby increasing clinical heterogeneity across participants. Moreover, both cohorts lack complete and reliable cancer‐specific mortality data, restricting us to adopt all‐cause mortality as the sole study endpoint and limiting clinical interpretability. To mitigate these shortcomings, our team has launched an ongoing clinical study to collect real‐world data containing detailed cancer staging, laboratory indicators, and standardized survival information, with relevant findings to be reported in future research. Third, while weighted analyses and sensitivity analyses including multiple imputation of missing values and E‐value analyses confirmed the consistency of the ABSI‐mortality association in the CHARLS cohort, the small sample size may still reduce effect estimate precision. We will further expand the sample size in future clinical studies to validate our findings in larger independent cohorts. Furthermore, visceral obesity indices and inflammatory biomarkers were assessed only at a single time point, which cannot capture their dynamic longitudinal changes and may affect the observed associations. The reported mediating effect is merely intended to offer preliminary epidemiological clues for the potential mechanistic pathway underlying the link between lipid metabolism and survival outcomes among cancer survivors, rather than establishing definitive causal mediation. Future well‐designed prospective studies with repeated longitudinal measurements are warranted to further verify these mechanistic relationships. Additionally, preclinical studies, including cellular and animal experiments, would be valuable to validate the potential mechanistic links, such as directly assessing whether manipulating neutrophil function or abundance alters the relationship between visceral adiposity (modeled in relevant animal models) and cancer‐related survival outcomes. Conclusions In conclusion, our findings demonstrate that ABSI, but not BMI or other visceral obesity indices, is a robust predictor of all‐cause mortality among cancer survivors across diverse populations. The observed partial mediation by neutrophils, an indicator of inflammation, suggests a potential correlative pathway linking visceral adiposity to survival, though this mechanistic insight should be interpreted with caution. These results underscore the importance of body shape assessment in survivorship care and support targeting visceral obesity to improve long‐term outcomes. Notably, more prospective studies are warranted to further validate the predictive utility of ABSI and clarify its clinical applicability in routine risk assessment for cancer survivors. Author Contributions Wei Zhang: conceptualization, project administration, resources, writing – review and editing. Qiang Li: writing – review and editing, writing – original draft, formal analysis, software, visualization, funding acquisition. Yao Wang: writing – review and editing, methodology, data curation, investigation. Qingchun Liu: data curation, supervision, validation. Funding This study was supported by the Science and Technology Research Project of Hanzhong (Grant. No: SKJJKJGG09; Qiang Li). Ethics Statement The authors have nothing to report. Consent The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Figure S1: Optimal cutoff values of the six visceral obesity indices and BMI using X‐tile software in the NHANES cohort. Figure S2: Optimal cutoff values of the six visceral obesity indices and BMI using X‐tile software in the CHARLS cohort. Figure S3: Weighted Kaplan–Meier curves for cancer survivors in the NHANES cohort, highlighting indices with no statistically significant differences post‐stratification. Figure S4: Kaplan–Meier curves for cancer survivors in the NHANES cohort. Figure S5: Weighted Kaplan–Meier curves for cancer survivors in the CHARLS cohort, highlighting indices with no statistically significant differences post‐stratification. Figure S6: Kaplan–Meier curves for cancer survivors in the CHARLS cohort. Figure S7: VIF of the six visceral obesity indices and BMI with each 1‐SD increase in Model 5 among NHANES cohort. Figure S8: VIF of the six visceral obesity indices and BMI levels in Model 5 among NHANES cohort. Figure S9: VIF of the six visceral obesity indices and BMI with each 1‐SD increase in Model 5 among CHARLS cohort. Figure S10: VIF of the six visceral obesity indices and BMI levels in Model 5 among CHARLS cohort. Figure S11: Restricted cubic spline of the linear trends between ConI with all‐cause mortality of the cancer survivors among NHANES and CHARLS cohorts. Figure S12: Restricted cubic spline of the linear trends between VAI with all‐cause mortality of the cancer survivors among NHANES and CHARLS cohorts. Figure S13: Restricted cubic spline of the linear trends between CVAI with all‐cause mortality of the cancer survivors among NHANES and CHARLS cohorts. Figure S14: Restricted cubic spline of the linear trends between METS‐VF with all‐cause mortality of the cancer survivors among NHANES and CHARLS cohorts. Figure S15: Restricted cubic spline of the linear trends between LAP with all‐cause mortality of the cancer survivors among NHANES and CHARLS cohorts. Figure S16: Restricted cubic spline of the linear trends between BMI with all‐cause mortality of the cancer survivors among NHANES and CHARLS cohorts. Figure S17: Weighted Kaplan–Meier curves and Kaplan–Meier curves for cancer survivors in the NHANES and CHARLS cohorts with non‐missing survival time data according to different levels of the ABSI. Table S1: Subgroup analyses of the association between ABSI and all‐cause mortality in the NHANES and CHARLS cohorts. Table S2: Description of the baseline characteristics between participants with and without missing values of the NHANES cohort. Table S3: Description of the baseline characteristics of the NHANES cohort following the imputation of missing values. Table S4: Weighted multivariable Cox regression analyses of the associations between six visceral obesity indices, BMI, and all‐cause mortality among cancer survivors in the NHANES cohort after imputation of missing values. Table S5: Description of the baseline characteristics of the CHARLS cohort following the imputation of missing values. Table S6: Weighted multivariable Cox regression analyses of the associations between six visceral obesity indices, BMI, and all‐cause mortality among cancer survivors in the CHARLS cohort after imputation of missing values. Table S7: Mediation analysis of the role of inflammatory biomarkers in the association between ABSI and all‐cause mortality in the NHANES cohort after imputation of missing values. Table S8: Weighted multivariable Cox regression models analysis in the CHARLS cohort using the same cutoff values of ABSI as in the NHANES cohort. Table S9: Weighted multivariable Cox regression models analysis of the relationship between ABSI (quartile‐based categorization) and all‐cause mortality among cancer survivors in the NHANES cohort. Table S10: Weighted multivariable Cox regression models analysis of the relationship between ABSI (quartile‐based categorization) and all‐cause mortality among cancer survivors in the CHARLS cohort. Table S11: Weighted multivariable Cox regression model analysis in the NHANES and CHARLS cohorts with non‐missing survival time data in Model 5. Table S12: E‐value of association between ABSI and all‐cause mortality in the NHANES and CHARLS cohorts.